Stockreport

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melano [Read more]